Zafgen to Participate in Upcoming Investor Conferences

Allena Pharmaceuticals Initiates Patient Treatment in Third Phase 2 Trial of ALLN-177 for Secondary Hyperoxaluria

Editas Medicine Announces Closing of Initial Public Offering and Full Exercise of Option to Purchase Additional Shares

Global Blood Therapeutics Announces Changes to Board of Directors

Blueprint Medicines Appoints Lonnel Coats to Board of Directors